Forbes July 8, 2024
The pharmaceutical industry’s attempts to impede implementation of Medicare prescription drug price negotiations—enacted under the Inflation Reduction Act—suffered a 5th consecutive setback last week when a federal judge in Connecticut ruled against the drug maker Boehringer Ingelheim. As STAT News describes, the judge denied the company’s claims that Medicare drug price negotiations are unconstitutional.
And a federal judge ruled against manufacturers Bristol Myers Squibb and Janssen Pharmaceuticals in April concerning their lawsuits challenging the constitutionality of giving Medicare the capacity to negotiate drug prices. Since the April ruling, both companies indicated they will appeal the decision.
In May, the Pharmaceutical Research and Manufacturers of America, the Global Colon Cancer Association and the National Infusion Center Association presented oral arguments in...
Today's Sponsors
Today's Sponsor